More
than 70,000 people worldwide are suffering from cystic fibrosis, suggests the Cystic Fibrosis Foundation Patient Registry. Approximately 1,000 new cases are diagnosed each year in the United States
alone.
Adherence to inhaled and oral therapies for cystic fibrosis
patients is discouragingly low, ranging 31-35% for inhaled
antibiotics. Programs to enhance adherence have had mixed success.
Cystic Fibrosis
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure
Advertisement
‘With Bluetooth technology there is remarkable improvement in adherence to inhaled and oral therapies for cystic fibrosis patients.’
Tweet it Now
A new pilot study from Ventura County Medical Center in Ventura, California, shows remarkable improvement in adherence using Bluetooth technology. For 28 days, patients used a Bluetooth-enabled medication delivery and monitoring tool called eRapid™. The clinic used the technology to gain rapid feedback on nebulizer use and used the data to reward patients for adherence as a depression intervention method.
Results not
only showed 80% improvement in adherence but also 30%
improvement in measures of airflow limitation and frequency of flare-ups
of disease.
![Novel Low-Cost Sensor for Cystic Fibrosis Diagnosis Based on Citrate]( "Novel Low-Cost Sensor for Cystic Fibrosis Diagnosis Based on Citrate")
A newly developed fluorescent sensor is highly sensitive and highly selective for chloride, the key diagnostic marker in cystic fibrosis.
"eRapid™ decreases miscommunication and misunderstanding between the patient and the provider by replacing an error-prone self-reporting method with real-time data," says Dr. Chris Landon, lead researcher. "Ongoing assessment of the data by the health care team allows for active engagement between the patient and provider promoting shared decision making in individualized therapy and cognitive behavioral interventions."
Source: Eurekalert
Novel Low-Cost Sensor for Cystic Fibrosis Diagnosis Based on Citrate
A newly developed fluorescent sensor is highly sensitive and highly selective for chloride, the key diagnostic marker in cystic fibrosis.
Advertisement
"eRapid™ decreases miscommunication and misunderstanding between the patient and the provider by replacing an error-prone self-reporting method with real-time data," says Dr. Chris Landon, lead researcher. "Ongoing assessment of the data by the health care team allows for active engagement between the patient and provider promoting shared decision making in individualized therapy and cognitive behavioral interventions."
Source: Eurekalert
Low Cost Sensor Developed To Diagnose Cystic Fibrosis
Cystic fibrosis is a common genetic disease within the white population in the United States. The disease occurs in 1 in 2,500 to 3,500 white newborns.
Advertisement
 Gene Therapy May Help Treat Cystic Fibrosis Lung DiseaseTwo gene therapy vectors partially correct lung disease in a pig model of cystic fibrosis. | Advertisement
|
Advertisement
